	US 12,269,882 B1
	Antigen binding polypeptides
Kevin M. Friedman, Boston, MA (US); Molly R. Perkins, Milton, MA (US); Connor S. Dobson, Washington, DC (US); Stephen L. Sazinsky, Winchester, MA (US); Shannon G. Contrastano, Auburndale, MA (US); Emily Thompson Beura, Mansfield, MA (US); Cory Ahonen, Lebanon, NH (US); and Andrew Avery, Lebanon, NH (US)
Assigned to Kelonia Therapeutics, Inc., Boston, MA (US)
Filed by Kelonia Therapeutics, Inc., Boston, MA (US)
Filed on Oct. 17, 2024, as Appl. No. 18/919,069.
Application 18/919,069 is a continuation of application No. PCT/US2024/048295, filed on Sep. 25, 2024.
Claims priority of provisional application 63/618,880, filed on Jan. 8, 2024.
Claims priority of provisional application 63/540,332, filed on Sep. 25, 2023.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC C07K 16/2809 (2013.01) [C12N 15/86 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C12N 2740/15043 (2013.01); C12N 2830/50 (2013.01)]

30 Claims

1. An antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) comprising a CDRH1, a CDRH2, and a CDRH3 comprising the amino acid sequences set forth in SEQ ID NOs: 82, 83, and 84; a polypeptide linker; and a light chain variable region (VL) comprising a CDRL1, a CDRL2, and a CDRL3 comprising the amino acid sequences set forth in SEQ ID NOs: 86, 87, and 88.